Comparison of Efficacy and Safety after Administering High Potency Statin to High Risk Patients: Rosuvastatin 10 mg versus Atorvastatin 20 mg.
10.4070/kcj.2007.37.4.154
- Author:
Kyeong Ho YUN
1
;
Hyun Young PARK
;
Jun Ho CHOI
;
Mi Jin SONG
;
Eun Mi PARK
;
Yun Kyung KIM
;
Sang Jae RHEE
;
Eun Mi LEE
;
Je LEE
;
Nam Jin YOO
;
Nam Ho KIM
;
Seok Kyu OH
;
Jin Won JEONG
Author Information
1. Department of Cardiovascular Medicine, Wonkwang University Hospital, Iksan, Korea. jjwcar@wonkwang.ac.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Hydroxylmethyglutaryl-CoA reductase inhibitors;
Cholesterol;
Guideline
- MeSH:
Acute Coronary Syndrome;
Cholesterol;
Cholesterol, LDL;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*;
Lipoproteins;
Oxidoreductases;
Stroke;
Atorvastatin Calcium;
Rosuvastatin Calcium
- From:Korean Circulation Journal
2007;37(4):154-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Although the rate of prescribing hydroxylmethyglutaryl-CoA reductase inhibitors (statin) has recently increased, there is a large treatment gap between the guidelines and actual clinical practice. We studied the effect of high potency statin on the percentage of patients who achieve the target low density lipoprotein (LDL) cholesterol level, and we determined the changes of lipid profiles with using 10 mg of rosuvastatin and 20 mg of atorvastatin. MATERIALS AND METHODS: 222 consecutive patients with acute coronary syndrome or acute ischemic stroke were randomly assigned to either the group treated with rosuvastatin 10 mg (Group I) or atorvastatin 20 mg (Group II). We compared the percentage of patients who achieved the target LDL cholesterol level, and the percent change of the serum lipid profile from baseline to the 40th week between the two groups. RESULTS: 117 (52.7%) patients completed this study. When the target LDL cholesterol level was <100 mg/dL, there was no significant difference in the target attainment rate between the two groups (86.7% vs. 77.2%; respectively, p=0.182). When the target LDL cholesterol level was <70 mg/dL, 48.3% of Group I and 29.8% of Group II reached the goal (p=0.040). The LDL cholesterol level was reduced by 46.8% in Group I (p<0.001), and by 40.1% in Group II (p<0.001). However, the final level showed a trend to be lower in the rosuvastatin group (p=0.077). There were no serious side effects in both groups. The study drug was discontinued due to adverse events in 2 patients (2.6%) of Group I, and in 3 patients (3.8%) of Group II (p=0.523). CONCLUSION: This study showed that the reduction of LDL cholesterol was not statistically different between rosuvastatin 10 mg and atorvastatin 20 mg. However, fewer than half of the patients achieved the goal in both groups despite of high potency statin therapy. This suggests that more aggressive statin therapy is preferred for high risk patients.
